Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05490563 · ClinicalTrials.gov registry record · Phase 2
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
A Phase 2 study, sponsored by Seelos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT05490563 is a Phase 2 study that was terminated before completion, run by Seelos Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT05490563, a Phase 2 study, was terminated before completion, sponsored by Seelos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
Interventions
- DRUG Placebo
- DRUG SLS-005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2023-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05490563
The ClinicalTrials.gov registry entry for NCT05490563 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seelos Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05490563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05490563 about?
NCT05490563 is a clinical study titled "STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia". Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
What is the current status of trial NCT05490563?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2022-06-03. Estimated completion is 2023-11-24.
What interventions are being tested in trial NCT05490563?
The interventions under investigation include: Placebo (DRUG), SLS-005 (DRUG).
Who is sponsoring clinical trial NCT05490563?
This trial is sponsored by Seelos Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.